Table 5 Changes in parameters related to the metabolic syndrome and females sex hormones in postmenopausal BC patients during adjuvant anticancer treatment

Weight (kg)^a

76.4 ± 16.2

76.7 ± 15.5

75.9 ± 15.6

0.6

BMI (kg/m²)^b

26.3 [22.7; 30.8]

27.1 [23.5; 30.8]

25.8 [23.1; 30.6]

0.2

Waist (cm)^{a, g}

88.7 ± 11.1

90.1 ± 10.6

91.7 ± 10.9

0.1

Body fat (%)^a

38.5 ± 5.77

38.0 ± 5.65

38.6 ± 5.04

0.2

Lean body mass (kg)^a

43.5 ± 6.13

44.2 ± 5.53

43.2 ± 6.25

0.07

Bone mineral density (g/cm²)

1.08 ± 0.11

1.08 ± 0.09

1.09 ± 0.09

0.4

Total cholesterol (mmol/L)

5.56 ± 0.83

5.54 ± 1.03

5.73 ± 0.92

0.9

LDL (mmol/L)^a

3.24 ± 0.91

3.24 ± 0.99^h

3.43 ± 1.01

1.0

HDL (mmol/L)^a

1.73 ± 0.52

1.45 ± 0.38

1.64 ± 0.44

< 0.0001^e

Triglyceride (mmol/L)^b

1.15 [0.9; 1.2]

1.30 [1.11; 1.87]

1.15 [1.0; 1.39]

0.006 ^e

Glucose (mmol/L)^a

5.90 ± 0.61

5.83 ± 0.88

5.62 ± 0.51

0.5

Insulin (pmol/L)^b

41.1 [32.0; 52.8]

38.0 [29.2; 49.6]

38.6 [30.5; 49.0]

0.3

HOMA-IR

0.83 [0.66; 1.04]

0.76 [0.59; 0.98]

0.75 [0.59; 0.95]

0.2

HOMAβ

59.4 [52.7; 67.0]

57.9 [51.9; 64.6]

60.0 [51.9; 69.4]

0.6

HbA1c (mmol/mol)^a

37.0 ± 4.64

Not relevant^f

36.2 ± 4.73

Not relevant^f

Systolic blood pressure mmHg^a

119 ± 11.3

115 ± 11.4

116 ± 10.2

0.1

Diastolic blood pressure mmHg^a

72.4 ± 5.87

70.0 ± 6.96

72.3 ± 6.68

0.1

Hs-CRP (mg/L)^b

1.43 [0.76; 3.90]

1.41 [1.01; 4.73]

1.12 [1.01; 1.70]

0.8

CD163 (mg/L)

1.93 [1.77; 2.08]

1.99 [1.68; 2.40]

1.93 [1.67; 2.32]

0.5

CD206 (mg/L)

0.23 [0.18; 0.29]

0.28 [0.23; 0.32]

0.24 [0.18; 0.27]

0.1

MetSⁱ

5 (25%)

3 (15%)

3 (15%)

0.4

FSH (IU/L)

74.5 [62.2; 98.4]

72 [64.2; 88.7]

73.5 [61.5; 87.8]

0.3

LH (IU/L)

41.5 [36; 44.9]

39 [30.7; 42.9]

32.5 [30.1; 38.8]

0.5

Estradiol (pmol/L)

15 [15; 22.7]

15 [15; 18.6]

15 [15; 18.3]

0.3